Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Patruno, Cataldo; Fabbrocini, Gabriella; Longo, Giuseppe; Argenziano, Giuseppe; Ferrucci, Silvia; Stingeni, Luca; Peris, Ketty; Ortoncelli, Michela; Offidani, Annamaria; Amoruso, Giuseppe Fabrizio; Talamonti, Marina; Girolomoni, Giampiero; Grieco, Teresa; Iannone, Michela; Nettis, Eustachio; Foti, Caterina; Rongioletti, Franco; Corazza, Monica; Veneri, Michele Delli; Napolitano, Maddalena; Angileri, Luisa; Bianchelli, Tommaso; Borghi, Alessandro; Calabrese, Giulia; Chello, Camilla; Bello, Giacomo Dal; Dastoli, Stefano; Ferrillo, Maria; Galluzzo, Marco; Gori, Niccolò; Hansel, Katharina; Macchia, Luigi; Piras, Viviana; Provenzano, Eugenio; Ribero, Simone; Romanelli, Marco; Romita, Paolo

doi:10.1007/s40257-021-00597-5

Cited by 40 publications

(29 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, older patients and those with a longer disease duration were found to have better efficacy with dupilumab. Similar to the results of an Italian real-world study in which elderly patients (≥65 years) with severe AD treated with dupilumab showed significant and persistent improvement in EASI, Pruritus-NRS, Sleep-NRS, and DLQI at 16 weeks and 52 weeks compared with baseline ( 25 ). Identifying this characteristic will lead to more informed drug choices in the future.…”

Section: Discussionsupporting

confidence: 79%

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

Zhou

Peng

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundAtopic dermatitis (AD) is a common skin disease, but treatment of this disease has been challenging. Dupilumab is a new biological agent for AD that has been proven to be safe and effective in clinical trials. Although dupilumab was approved for listing in China in June 2020, real-world data about the application of dupilumab in China are lacking. This study aimed to collect and analyze real-world data on dupilumab among Chinese AD patients.MethodsDemographic and clinical data for 116 AD patients receiving dupilumab treatment were reviewed. The Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Numerical Rating Scale (NRS), Patient Oriented Eczema Measure (POEM), and Dermatology Quality of Life Index (DLQI) of patients were evaluated every 2 weeks from baseline to 16 weeks of treatment. Any adverse events during treatment were recorded.ResultsAmong the 116 patients in this study, baseline levels of IgE, eosinophils, and LDH were elevated in 62.79% (n = 86), 45.30% (n = 86), and 54.20% of patients (n = 48), respectively. The SCORAD index and POEM, DLQI, and NRS scores were significantly improved in all patients at 2 weeks (p < 0.0001), 4 weeks (p < 0.01), and 16 weeks (p < 0.001). EASI scores also improved significantly in all patients at 2 weeks (p < 0.01), 4 weeks (> 0.05), and 16 weeks (p < 0.01). However, 11 patients (9.48%) had no response. IgE and LDH levels (p > 0.05), Eosinophil counts (p < 0.01) in blood increased temporarily in the first 4 weeks and then decreased and stabilized during dupilumab treatment. Conjunctivitis was the most common adverse event (2.59%) among the patients. We found that the curative efficacy of dupilumab at 4th weeks was related to the patient’s age and course of disease. Nevertheless, there is no relationship between levels of eosinophils, IgE, LDH and the therapeutic efficacy of dupilumab.ConclusionThe real-world data in China showed that dupilumab can effectively treat AD and is well tolerated with a low incidence of adverse events.

show abstract

Section: Discussionsupporting

confidence: 79%

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

Zhou

Peng

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Real-world evidence of the effectiveness and safety of dupilumab for atopic dermatitis Accumulating real-world evidence has ensured the effectiveness and tolerable safety of dupilumab both in the short term and in the long term. The articles searched in PubMed and Google Scholar are shown in Table 1 (Ariëns et al, 2020, Ariëns et al, 2021, Faiz et al, 2019, Fargnoli et al, 2020, Fargnoli et al, 2019, Jang et al, 2020, Jo et al, 2020a, Kreeshan et al, 2021, Matsutani et al, 2020, Nettis et al, 2020b, Nettis et al, 2020c, Olesen et al, 2019, Patruno et al, 2021a, Patruno et al, 2021b, Quint et al, 2020, Ribero et al, 2020, Sears et al, 2020, Tauber et al, 2019, Uchida et al, 2021, Uchida et al, 2019. Patruno et al reported the effectiveness and safety of dupilumab in elderly patients with AD in real life (Patruno et al, 2021a, Patruno et al, 2021b.…”

Section: Effectiveness and Safety Of Dupilumab For Atopic Dermatitis In The Real Worldmentioning

confidence: 99%

“…The articles searched in PubMed and Google Scholar are shown in Table 1 (Ariëns et al, 2020, Ariëns et al, 2021, Faiz et al, 2019, Fargnoli et al, 2020, Fargnoli et al, 2019, Jang et al, 2020, Jo et al, 2020a, Kreeshan et al, 2021, Matsutani et al, 2020, Nettis et al, 2020b, Nettis et al, 2020c, Olesen et al, 2019, Patruno et al, 2021a, Patruno et al, 2021b, Quint et al, 2020, Ribero et al, 2020, Sears et al, 2020, Tauber et al, 2019, Uchida et al, 2021, Uchida et al, 2019. Patruno et al reported the effectiveness and safety of dupilumab in elderly patients with AD in real life (Patruno et al, 2021a, Patruno et al, 2021b. Halling et al reported a systematic review and meta-analysis of real-world data on the efficacy and safety of dupilumab in patients with AD (Halling et al, 2021).…”

Section: Effectiveness and Safety Of Dupilumab For Atopic Dermatitis In The Real Worldmentioning

confidence: 99%

“…The articles searched in PubMed and Google Scholar are shown in Table 1 ( Ariëns et al., 2021 , 2020 ; Armario-Hita et al., 2019 ; Faiz et al., 2019 ; Fargnoli et al, 2020 , 2019 ; Ferrucci et al., 2020 ; Jang et al., 2020 ; Jo et al., 2020a , 2020b ; Kim et al., 2020 ; Kreeshan et al., 2021 ; Matsutani et al., 2020 ; Nettis et al., 2020b , 2020c ; Olesen et al., 2019 ; Patruno et al., 2021a , 2021b ; Quint et al., 2020 ; Ribero et al., 2020 ; Sears et al., 2021 ; Tauber et al., 2019 ; Tavecchio et al., 2020 ; Uchida et al., 2021 , 2019 ; Wang et al., 2020 ; Yamauchi et al., 2021 ). Patruno et al. (2021a , 2021b) reported the effectiveness and safety of dupilumab in elderly patients with AD in real life.…”

Section: Effectiveness and Safety Of Dupilumab For Ad In The Real Worldmentioning

confidence: 99%

“…A total of 61 patients (22.51%) reported adverse events, conjunctivitis and flushing being the most frequent adverse events. Patruno et al (2021a) Italy 52 105 ND Data of elderly patients (aged ≥ 65 years) with severe (EASI ≥24) AD treated with dupilumab were studied. The mean EASI percentage improvement from baseline was 56.0%, 83.9%, and 87.2% after 16, 32, and 52 weeks, respectively.…”

Section: Effectiveness and Safety Of Dupilumab For Ad In The Real Worldmentioning

confidence: 99%

See 2 more Smart Citations

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System

et al. 2021

View full text Add to dashboard Cite

Objectives Dupilumab was the first biologic approved to treat chronic rhinosinusitis with nasal polyps (CRSwNP). While the risk of adverse events in phase‐III clinical trials was low, dupilumab‐associated adverse reactions (DAR) with real‐world use is unknown and potentially under‐reported. We aimed to evaluate DAR for CRSwNP treatment (CRSwNP‐tx) using the FDA Adverse Event Reporting System (FAERS). Study Design Retrospective database study. Methods FAERS was queried for DAR from 2019Q1 to 2021Q2. Individual DAR (iDAR) were categorized and quantitatively compared between treatment groups (CRSwNP, asthma, atopic dermatitis). Zero‐truncated Poisson regression was modeled to predict the number of iDAR, and logistic regression was modeled to predict serious DARs. Results There were 15,411 DAR observations; 911 for CRSwNP‐tx, of which 121 (13.3%) had serious reactions and 3 died. Common CRSwNP‐tx iDAR were dermatologic (13.9%), generalized (13.3%), and injection‐site (10.8%) symptoms. The number of CRSwNP‐tx iDAR was 2.99 [2.81, 3.17], compared to 3.44 [3.32, 3.56] for asthma and 3.18 [3.13, 3.24] for atopic dermatitis (Kruskal‐Wallis test, P < .001). For CRSwNP‐tx, iDAR reported‐risk‐ratio was 0.84 [0.77, 0.92] among men and 1.12 [1.04, 1.22] among older adults (>50). Serious DAR reported‐odds‐ratio was 1.37 [0.91, 2.04] among men and 1.39 [0.93, 2.08] among older adults. Conclusions While there are limitations with FAERS, this analysis suggests CRSwNP‐tx is associated with fewer iDAR compared with other treatment indications. More iDAR are experienced among women and older adults, but men tend to have more serious DAR. Level of Evidence 3 Laryngoscope, 132:2307–2313, 2022

show abstract

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Cited by 40 publications

References 10 publications

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System

Contact Info

Product

Resources

About